All Stories

As Xarelto's decline picks up speed, Bayer doesn't expect pharma growth until 2027

After Bayer's blood thinner Xarelto saw a sales decline of 600 million euros ($646 million) in 2024 because of generic competition, the company is projecting a sharper fall of between 1 billion and 1.5 billion euros in 2025.

Mar 5, 2025 - 17:23
 0
As Xarelto's decline picks up speed, Bayer doesn't expect pharma growth until 2027
After Bayer's blood thinner Xarelto saw a sales decline of 600 million euros ($646 million) in 2024 because of generic competition, the company is projecting a sharper fall of between 1 billion and 1.5 billion euros in 2025.
Read More

Tags:

Previous Article

Top Hotel POS Integrations to Watch in 2025

Next Article

Lilly’s 1st DTC Ebglyss campaign highlights eczema’s effects on a range of skin ...

Related Posts

UPDATED: Merck KGaA sets its sights on acquisition of Ogsiveo-maker SpringWorks

UPDATED: Merck KGaA sets its sights on acquisition of O...

Feb 11, 2025  0

Quantoom, DNA Script and EVA Pharma link up in renewed push to bring mRNA vaccine autonomy to Africa and beyond

Quantoom, DNA Script and EVA Pharma link up in renewed ...

Feb 9, 2025  0

J&J CEO broke a stalemate and facilitated the $14.6B Intra-Cellular buyout in a whirlwind month: filing

J&J CEO broke a stalemate and facilitated the $14.6B In...

Feb 9, 2025  0